Latest California Healthline Stories
Senator Grassley Launches Inquiry Into Orphan Drugs After KHN Investigation
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
Five Quick Ways New HHS Secretary Tom Price Could Change The Course Of Health Policy
Tom Price will have significant authority to rewrite the rules for the Affordable Care Act.
Una investigación de Kaiser Health News analiza las acciones de compañias farmacéuticas para manipular los precios de medicamentos huérfanos, utilizados para tratar enfermedades raras.
Drugmakers Manipulate Orphan Drug Rules To Create Prized Monopolies
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren’t new or were repurposed multiple times, an investigation shows.
In Search Of A Vaccine To Vanquish The Plague
The scourge of the Middle Ages could still be pretty scary as a bioterrorism weapon, so scientists are trying to find a way to immunize people against it.
Grilled About Deadly Superbug Outbreaks, Execs At Scope Maker Olympus Take Fifth
Lawyers who deposed top company officials in a civil case say they declined to answer questions about their failure to warn American hospitals of infection risks. Industry giant Olympus also is the subject of a criminal probe.
Grab Bag Of Goodies In 21st Century Cures Act
A breakdown of winners — and a few losers — in the sprawling Cures Act approved by the House.
A Frenzy Of Lobbying On 21st Century Cures
Three lobbyists for every member of Congress in a push to pass a bill that increases research funding and speeds up approvals.
Deadly Infections Linked To Heart Surgery Device Highlight Holes In FDA Monitoring
The federal agency took 14 months to warn the public about the potential for infections. Officials say they acted as fast as they could.
Long-Stalled FDA Reform Sits On Senate’s Lame-Duck Calendar
The legislation would give federal officials more flexibility in evaluating the effectiveness and safety of drugs and devices and add billions of dollars to NIH funding. But critics say it could endanger patients’ safety and doesn’t do enough to stop spiraling drug prices.